About the Company
We do not have any company description for Cytek Biosciences, Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Laboratory Analytical Instruments
Employees
555
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cytek Biosciences, Inc.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. At this time, I ...
Cytek Biosciences Inc (CTKB) Q2 2025 Earnings Report Preview: What To Look For
Cytek Biosciences Inc (NASDAQ:CTKB) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 ...
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ...
Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ETCompany ParticipantsPaul Goodson - Investor RelationsWenbin ...
Diversified Trust Co Acquires Shares of 24,532 Cytek Biosciences, Inc ...
Cytek Biosciences, Inc. has a 12-month low of $2.37 and a 12-month high of $7.63. The stock has a market capitalization of $457.24 million, a PE ratio of -40.11 and a beta of 1.33.
Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ETCompany ParticipantsPaul Goodson – Investor ...
Cytek® Biosciences Adds Ability to Detect ... - Markets Insider
About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high ...
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue ... - Nasdaq
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue ... - Nasdaq
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Call Transcript
Cytek Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by.
Similar Companies
Loading the latest forecasts...